-
Jan 15, 2025 | 
patientcareonline.com | Peter McAllister |Grace Halsey
Near the end of 2024, Patient Care© interviewed Peter McAllister, MD, a practicing neurologist and active clinical trial investigator on a wide range of topics in migraine spanning research, discovery, disappointments, and a look ahead to 2025. At the end we asked McAllister to imagine he had 3 wishes for patients with migraine that would come to fruition over the next 10 to 15 years. He explains those wishes and the thought behind them in the short video above.
-
Jan 14, 2025 | 
patientcareonline.com | Peter McAllister |Grace Halsey
The following transcript has been edited for clarity. Patient Care: What areas are you most eager to continue or begin work on in 2025? McAllister: So, these new neuropeptides are really interesting. We're also wrapping up a few neurotoxin trials, and we’re hopeful that they might be the exception and show positive results. One area we’re focusing on is post-traumatic headache, which we haven’t done much work on in the past.
-
Jan 13, 2025 | 
patientcareonline.com | Peter McAllister |Grace Halsey
January 13, 2025By Migraine expert Peter McAllister, MD, a long-time principal investigator for migraine studies, wonders if study design in this area needs to be re-evaluated.
-
Jan 10, 2025 | 
patientcareonline.com | Peter McAllister |Grace Halsey
"The CGRP-targeting migraine therapies are a first-line option for migraine prevention.
-
Jan 7, 2025 | 
patientcareonline.com | Peter McAllister |Grace Halsey
Peter McAllister, MD, a neurologist and long-time principal investigator for landmark clinical trials of new migraine therapies, spoke with Patient Care© recently about the research he feels was headline news in the specialty in the last year and what those advances will mean for clinical care.
-
Jan 7, 2025 | 
patientcareonline.com | Peter McAllister |Grace Halsey
January 7, 2025By The onset of migraine with its wide range of symptoms may be telegraphed as early as 2 days before by the frequency of neuronal oscillation deep in the brain.
-
Jun 24, 2024 | 
headachejournal.onlinelibrary.wiley.com | Andrew Blumenfeld |David Kudrow |Peter McAllister |Joe Hirman
CM chronic migraine HIT-6 6-item Headache Impact Test ICHD-3β International Classification of Headache Disorders, 3rd edition, beta MIDAS Migraine Disability Assessment MOH medication-overuse headache PGIC Patient Global Impression of Change PI-MBS patient-identified most bothersome symptom SD standard deviation SE standard error SF-36 36-item Short-Form Health Survey INTRODUCTION Medication-overuse headache (MOH) is a secondary headache disorder that develops in some patients who frequently...
-
May 20, 2024 | 
neurologylive.com | Peter McAllister
WATCH TIME: 5 minutes"This is the first big change in the whole neurotoxin market in 3 decades, ushering in a whole new era in which we will have personalized medicine for patients with cervical dystonia."Research shows that botulinum toxin injections have treated conditions for over 30 years yet despite this, it has become common for re-emergence of early symptom among patients.
-
Jun 23, 2023 | 
ethicaltrade.org | Peter McAllister
25 years since our foundation ETI continues to thrive and grow our reach and impact. Since 1998, our mission has been to advocate for the most vulnerable workers. While great strides have been made since our inception, workers today face many of the same issues and challenges of the late 90s, with the added complexities of scale and evolving crises, from conflicts to climate change.
-
May 25, 2023 | 
ethicaltrade.org | Peter McAllister
In a new open letter from our Executive Director, Peter McAllister, ETI is calling on Members of the European Parliament to vote in favour of the latest compromise for the Corporate Sustainability Due Diligence Directive, proposed by the Legal Affairs Committee (JURI), on 1 June. We urge business and other stakeholders to contact their MEPs directly asking them to do the same. Find our open letter in full below.
